Johnson & Johnson (NYSE:JNJ) Stock Price Down 0% – Here’s What Happened

Johnson & Johnson (NYSE:JNJ) fell 0% during trading on Friday . The stock traded as low as $155.06 and last traded at $155.62. 1,143,948 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 7,865,409 shares. The stock had previously closed at $155.66.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Bank of America reduced their price objective on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $171.82.

Johnson & Johnson Stock Performance

The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a fifty day moving average of $157.89 and a two-hundred day moving average of $154.29. The stock has a market capitalization of $370.49 billion, a P/E ratio of 23.15, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio is 57.84%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Sulzberger Capital Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter worth $453,000. Oregon Pacific Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $949,000. Horan Securities Inc. increased its stake in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after buying an additional 90 shares during the period. Strategic Financial Concepts LLC raised its position in shares of Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after buying an additional 1,271 shares in the last quarter. Finally, KPP Advisory Services LLC boosted its holdings in shares of Johnson & Johnson by 4.7% in the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock valued at $1,662,000 after acquiring an additional 515 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.